Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Thyroid Nodule 1Thyroid Neoplasms 1Thyroid Diseases 1Solitary Fibrous Tumors 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Parathyroid Neoplasms 1Parathyroid Diseases 1Ovarian Neoplasms 1Opioid-Related Disorders 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Lower Urinary Tract Symptoms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Capsules × Clear all
NCT04336124 2022-11-28

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

TaiRx, Inc.

Phase 1 Completed
5 enrolled
Tumor-Agnostic

Neoplasms

NCT04727138 2022-05-16

3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546

Exscientia AI Limited

Phase 1 Completed
64 enrolled
Tumor-Agnostic

Neoplasms

NCT02536391 2016-11-02

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Genentech, Inc.

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡